Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024  - Episode 13

Perspectives of IMerge Study

, , , ,

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification
EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 
EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
EP. 4: Review of the COMMANDS Trial
EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice
EP. 7: Treatment Decision-Making Based on the COMMANDS Trials
EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data
EP. 10: Safety Profile of Available Frontline Treatments LR-MDS
EP. 11: 1L treatment of lower-risk MDS beyond luspatercept
EP. 12: Sequencing Second-Line Treatments for LR-MDS
Now Viewing
EP. 13: Perspectives of IMerge Study
EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS
  1. Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS.
    1. Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet. 2024;403(10423):249-260.)
    2. Dr Komrokji: How does the latest follow up from the IMergestudy support the use of imetelstat in patients with LR-MDS?

Related Content:

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 ClinicalOncLive Peer Exchange® Video Series
Single-Agent Immune Therapy in UC: The Need for More
Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice